Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04654221 · ClinicalTrials.gov registry record
Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery
A clinical trial, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04654221: Clinical Trial study, sponsored by Quark Pharmaceuticals.
NCT04654221 is a clinical trial that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04654221 was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
To evaluate the differences between serum cystatin C based estimated glomerular filtration rate (eGFRcys), serum creatinine based eGFR (eGFRcreat) and measured glomerular filtration rate (mGFR) in subjects at high risk for acute kidney injury (AKI) approximately 90 days following cardiac surgery
Primary Outcome
The primary measure will be the comparison of the P(30) and P(10) between eGFR based on serum cystatin C (eGFRcys) and eGFR based on serum creatinine (eGFRcreat). P(30) and P(10) are defined as the percentage of subjects whose eGFR is within 30% (10%) of the iohexol-based mGFR.
Interventions
- DIAGNOSTIC_TEST mGFR by iohexol clearance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2021-03-26 |
Why NCT04654221 stopped before completion
NCT04654221 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which mGFR by iohexol clearance is the first listed.
NCT04654221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04654221 about?
NCT04654221 is a clinical study titled "Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery". To evaluate the differences between serum cystatin C based estimated glomerular filtration rate (eGFRcys), serum creatinine based eGFR (eGFRcreat) and measured glomerular filtration rate (mGFR) in subjects at high risk for acute kidney injury (AKI) approximately 90 days following cardiac surgery
What is the current status of trial NCT04654221?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2020-02-21. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT04654221?
The interventions under investigation include: mGFR by iohexol clearance (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04654221?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI